Peptide Companion
Back to catalog
Peptide Companion
single
Cognitive
Vial: 5 mg

Semax (5 mg Vial)

Semax is a synthetic heptapeptide analog of the ACTH(4–10) fragment, originally developed in Russia for its neuroprotective, nootropic, and neurotrophic properties. It has been studied for cognitive enhancement, cerebrovascular recovery, and optic neuropathy support. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Dose
0.3–0.6 mg per injection
Frequency
Once or twice daily
Timing
Morning and/or afternoon
Duration
4–8 weeks

Nootropic peptide. Enhances focus and cognitive function. BDNF upregulation.

Dosing Schedule
WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–2200 mcg12 units (0.12 mL)
Weeks 3–4300 mcg18 units (0.18 mL)
Weeks 5–6400 mcg24 units (0.24 mL)
Weeks 7–12500 mcg30 units (0.30 mL)
Supplies Needed
  • •Peptide Vials (Semax, 5 mg each):
  • •Insulin Syringes (U‑100):
  • •Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
References

  • Neurochemical Journal (2023)

    Voronina T.A. Cognitive Impairment and Nootropic Drugs: Mechanism of Action and Spectrum of Effects. Discusses Semax pharmacology and administration routes.

    View source

  • Vidal Drug Manual (2021)

    Official prescribing information for Semax 0.1% intranasal formulation; human dosing guidelines, schedule, and storage requirements.

    View source

  • Zhurnal Nevrologii i Psikhiatrii (2018)

    Gusev E.I. et al. Efficacy of Semax in treatment of patients at different stages of ischemic stroke. Clinical trial of 6,000 mcg/day intranasal in 10‑day courses.

    View source

  • Neuroscience and Behavioral Physiology (2012)

    Manchenko D.M. et al. Nootropic and Analgesic Effects of Semax Given via Different Routes. Compares intranasal vs injection route efficacy.

    View source

  • Zh Vyssh Nerv Deiat (1997)

    Ashmarin I.P. et al. A nootropic analog of adrenocorticotropic hormone 4–10 — Semax. Early characterization of nootropic properties and dosing.

    View source

  • Vestnik Oftalmologii (2001)

    Kurysheva N.I. et al. Semax in treatment of glaucomatous optic neuropathy. Human study (36 patients); ~1 month daily Semax with no significant adverse effects.

    View source

  • CDC

    Vaccine administration: subcutaneous route (angle/site; no aspiration)

    View source

  • CDC (Subcut Injection PDF)

    Technique diagram and site guidance for subcutaneous injections

    View source

  • NCBI Bookshelf

    Best practices for injection (asepsis, preparation, and administration)

    View source

  • Subcutaneous Drug Injection Review (PMC)

    Pharmacologic considerations of the subcutaneous route

    View source

  • Pharmaceutics (2022)

    Deigin V.I. et al. Development of Peptide Biopharmaceuticals in Russia. Overview of Russian peptide drugs including Semax formulations and stability.

    View source

  • Drug Testing and Analysis (2023)

    Jędrejko K. et al. Unauthorized ingredients in “nootropic” dietary supplements. Notes Semax use as an unapproved nootropic, including intranasal use in humans.

    View source

  • Frontiers in Neuroscience (2017)

    Dolgikh V.T. et al. Semax as a universal drug for therapy and research. Review of intranasal delivery, bioavailability limitations, and clinical pharmacology across indications.

    View source

Educational content adapted from peptidedosages.com. Not medical advice.